Metastatic Prostate Cancer — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for metastatic prostate cancer. 9 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
9
Active US patents
20/100
Avg vulnerability
$1.6B
Annual revenue covered

Originators in Metastatic Prostate Cancer

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bayer 9 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating metastatic prostate cancer. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
30
1
33
3
36
1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Nubeqa
darolutamide
 Bayer 9 20 $1.6B 2030-10-27

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9657003 Nubeqa method of use 51 2030-10-27
8975254 Nubeqa method of use 45 2033-03-25
10835515 Nubeqa method of use 45 2036-01-28
12329742 Nubeqa formulation 38 2042-06-17
11046713 Nubeqa composition of matter 0 2030-10-27
10711013 Nubeqa composition of matter 0 2030-10-27
10383853 Nubeqa composition of matter 0 2036-01-28
10010530 Nubeqa composition of matter 0 2036-01-28
11168058 Nubeqa composition of matter 0 2038-02-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11168058 Nubeqa composition of matter 0 2038-02-27
10383853 Nubeqa composition of matter 0 2036-01-28
10010530 Nubeqa composition of matter 0 2036-01-28
10711013 Nubeqa composition of matter 0 2030-10-27
11046713 Nubeqa composition of matter 0 2030-10-27
12329742 Nubeqa formulation 38 2042-06-17
10835515 Nubeqa method of use 45 2036-01-28
8975254 Nubeqa method of use 45 2033-03-25
9657003 Nubeqa method of use 51 2030-10-27

Related